Human Leukocyte Antigen Class I and Programmed Death-Ligand 1 Coexpression Is an Independent Poor Prognostic Factor in Adenocarcinoma of the Lung
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: Both human leukocyte antigen (HLA) class I and programmed death-ligand 1 (PDL1) molecules are known to play important roles in cancer immunity. In this study, we evaluated HLA class I expression in resected adenocarcinoma of the lung, and investigated its prognostic impact in correlation with PD-L1 expression. Methods: HLA class I and PD-L1 expression was evaluated by immunohistochemistry in a total of 403 resected lung adenocarcinomas using tissue microarray. Correlations between the expression of HLA class I/PD-L1 and clinicopathologic features and prognostic significance were analyzed. Results: HLA class I expression was reduced in 91.6% of adenocarcinoma, and more frequently reduced in patients with younger age, absence of vascular invasion, and low pathologic stage (p = .033, p = .007, and p = .012, respectively). Positive PD-L1 expression in tumor cells was 16.1% (1% cut-off), and associated with poor differentiation, presence of vascular invasion and nodal metastasis (p < .001, p = .002, and p = .032, respectively). On survival analysis, HLA class I or PD-L1 expression alone did not show any statistical significance. On the integrated analysis, HLA class I (+)/PD-L1 (+) subgroup showed a significantly shorter overall survival than other groups (p = .001). Multivariate analysis revealed that coexpression of HLA class I and PD-L1 was an independent poor prognostic factor of lung adenocarcinoma. (p < .001; hazard ratio, 6.106; 95% confidence interval, 2.260 to 16.501). Conclusions: Lung adenocarcinoma with coexpression of HLA class I and PD-L1 was associated with poor prognosis. This subgroup may evade immune attack by expressing PD-L1 protein despite HLA expression.
Abstract
Background: Both human leukocyte antigen (HLA) class I and programmed death-ligand 1 (PDL1) molecules are known to play important roles in cancer immunity. In this study, we evaluated HLA class I expression in resected adenocarcinoma of the lung, and investigated its prognostic impact in correlation with PD-L1 expression. Methods: HLA class I and PD-L1 expression was evaluated by immunohistochemistry in a total of 403 resected lung adenocarcinomas using tissue microarray. Correlations between the expression of HLA class I/PD-L1 and clinicopathologic features and prognostic significance were analyzed. Results: HLA class I expression was reduced in 91.6% of adenocarcinoma, and more frequently reduced in patients with younger age, absence of vascular invasion, and low pathologic stage (p = .033, p = .007, and p = .012, respectively). Positive PD-L1 expression in tumor cells was 16.1% (1% cut-off), and associated with poor differentiation, presence of vascular invasion and nodal metastasis (p < .001, p = .002, and p = .032, respectively). On survival analysis, HLA class I or PD-L1 expression alone did not show any statistical significance. On the integrated analysis, HLA class I (+)/PD-L1 (+) subgroup showed a significantly shorter overall survival than other groups (p = .001). Multivariate analysis revealed that coexpression of HLA class I and PD-L1 was an independent poor prognostic factor of lung adenocarcinoma. (p < .001; hazard ratio, 6.106; 95% confidence interval, 2.260 to 16.501). Conclusions: Lung adenocarcinoma with coexpression of HLA class I and PD-L1 was associated with poor prognosis. This subgroup may evade immune attack by expressing PD-L1 protein despite HLA expression.
참고문헌 (22)
- 심효섭, "Molecular Testing of Lung Cancers", Journal of Pathology and Translational Medicine, 51(3), pp.242~254 (2017), 대한병리학회[DOI]
- Torre LA, "Cancer statistics for Asian Americans, Native Hawaiians, and Pacific Islanders, 2016 : converging incidence in males and females", CA Cancer J Clin, 66, pp.182~202 (2016)
- Somasundaram A, "The next generation of immunotherapy : keeping lung cancer in check", J Hematol Oncol, 10, pp.87~ (2017)
- Domagala-Kulawik J, "The role of the immune system in non-small cell lung carcinoma and potential for therapeutic intervention", Transl Lung Cancer Res, 4, pp.177~190 (2015)
- Concha-Benavente F, "Immunological and clinical significance of HLA class I antigen processing machinery component defects in malignant cells", Oral Oncol, 58, pp.52~58 (2016)
- Campoli M, "HLA antigen changes in malignant cells : epigenetic mechanisms and biologic significance", Oncogene, 27, pp.5869~5885 (2008)
- Hirai A, "Prognostic impact of programmed death-ligand 1 expression in correlation with human leukocyte antigen class I expression status in stage I adenocarcinoma of the lung", J Thorac Cardiovasc Surg, 155, pp.382.e1~392.e1 (2018)
- Kikuchi E, "HLA class I antigen expression is associated with a favorable prognosis in early stage nonsmall cell lung cancer", Cancer Sci, 98, pp.1424~1430 (2007)
- Ramnath N, "Is downregulation of MHC class I antigen expression in human non-small cell lung cancer associated with prolonged survival", Cancer Immunol Immunother, 55, pp.891~899 (2006)
- Edge SB, "AJCC cancer staging manual" (2010), Springer
- Travis WD, "The 2015 World Health Organization classification of lung tumors : impact of genetic, clinical and radiologic advances since the 2004 classification", J Thorac Oncol, 10, pp.1243~1260 (2015)
- Kim H, "Clinicopathological analysis and prognostic significance of programmed cell death-ligand 1 protein and mRNA expression in non-small cell lung cancer", PLoS One, 13, pp.e0198634~ (2018)
- Herbst RS, "Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer(KEYNOTE-010) : a randomised controlled trial", Lancet, 387, pp.1540~1550 (2016)
- Perea F, "HLA class I loss and PD-L1 expression in lung cancer : impact on T-cell infiltration and immune escape", Oncotarget, 9, pp.4120~4133 (2018)
- Campbell KS, "Structure", function of human killer cell immunoglobulin-like receptors : lessons from polymorphisms, evolution, crystal structures and mutations, 2011, pp.132, 315~325
- Ljunggren HG, "In search of the 'missing self' : MHC molecules and NK cell recognition", Immunol Today, 11, pp.237~244 (1990)
- Imai D, "The prognostic impact of programmed cell death ligand 1 and human leukocyte antigen class I in pancreatic cancer", Cancer Med, 6, pp.1614~1626 (2017)
- Mizukami Y, "Downregulation of HLA Class I molecules in the tumour is associated with a poor prognosis in patients with oesophageal squamous cell carcinoma", Br J Cancer, 99, pp.1462~1467 (2008)
- Umemoto Y, "Prognostic impact of programmed cell death 1 ligand 1 expression in human leukocyte antigen class I-positive hepatocellular carcinoma after curative hepatectomy", J Gastroenterol, 50, pp.65~75 (2015)
- Menon AG, "Down-regulation of HLA-A expression correlates with a better prognosis in colorectal cancer patients", Lab Invest, 82, pp.1725~1733 (2002)
- Ueda Y, "Clinical significance of HLA class I heavy chain expression in patients with gastric cancer", J Surg Oncol, 97, pp.451~455 (2008)
- Zhang M, "PD-L1 expression in lung cancer and its correlation with driver mutations : a meta-analysis", Sci Rep, 7, pp.10255~ (2017)